Emory University Study Maps Kratom Liver Metabolism Using Whole-Extract Analysis for the First Time

Why it matters

Understanding how the liver metabolizes kratom as a whole-plant mixture — not just individual alkaloids — is essential for assessing real-world drug interaction risks and toxicology. This Emory University study provides a new methodological framework for doing exactly that, and reveals that different kratom products generate meaningfully different metabolic profiles.

The big picture

Previous kratom metabolism studies examined one compound at a time, but users consume kratom as a complex plant mixture containing 50+ alkaloids that may compete for the same metabolic enzymes. The extent to which the surrounding alkaloid mixture changes the metabolism of key compounds like mitragynine has been unknown. This study used advanced mass spectrometry and molecular networking techniques — NIH-funded — to characterize mixture metabolism for the first time.

Key findings

• Different kratom chemotypes (extract types) produced significantly different amounts of 7-hydroxymitragynine (7-OH) during liver metabolism, meaning two kratom products with similar mitragynine content may produce very different amounts of the potent 7-OH metabolite in the body
• The study reported the first-ever characterization of speciofoline metabolism in human liver fractions
• An unreported phase II metabolite of mitragynine (likely 7-OH glucuronide) was identified and confirmed using isotopically labeled mitragynine
• Kratom alkaloids exhibit spontaneous stereoisomerization — non-enzymatic rearrangements that create additional biologically active compounds without any metabolic enzyme involvement
• The complexity of kratom mixture metabolism means that standard single-compound pharmacology studies cannot reliably predict whole-plant effects or drug interactions

What they say

According to corresponding authors Dean P. Jones and Cassandra L. Quave of Emory University, "understanding the competitive formation of active metabolites such as 7-hydroxymitragynine in the context of a mixture is a critical factor in understanding the overall pharmacology of kratom, as there are numerous commercially available chemotypes of the plant."

Bottom line

The kratom product a person consumes — not just the dose — determines what metabolites their liver produces, including how much of the potent 7-OH compound is generated, with profound implications for safety assessments and drug interaction predictions.